Mirum Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $521.3 | $336.9 | $186.4 | $77.1 | $19.1 |
| Operating income | -$22.1 | -$87.6 | -$109.2 | -$131.2 | -$173.4 |
| Net income | -$23.4 | -$87.9 | -$163.4 | -$135.7 | -$84.0 |
| Cash Flow Statement | |||||
| Free cash flow | $54.9 | $9.3 | -$71.1 | -$120.4 | -$132.8 |
Shares outstanding 61.0M · Free float 90.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.